NewAmsterdam Pharma Company N.V.

NASDAQ•NAMS

CEO: Dr. Michael Harvey Davidson FACC, Facp., M.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-02-09

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Contact Information

Gooimeer 2-35, Naarden, 1411 DC, Netherlands

31-35-206-2971

www.newamsterdampharma.com

Market Cap

$3.58B

P/E (TTM)

-17.5

19.7

Dividend Yield

52W High

$42.00

52W Low

$14.06

52W Range

61%

Rank59Top 87.6%

2.2

F-Score

Modified Piotroski Analysis

Based on 5-year fundamentals

Weak • 2.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2021-2025

Financial Dashboard

Q4 2025 Data

Revenue

$32.00K+0.00%

4-Quarter Trend

EPS

-$0.65+0.00%

4-Quarter Trend

FCF

-$40.98M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Phase 3 Trials Met Endpoints Obicetrapib met primary LDL-C lowering endpoints in BROADWAY and BROOKLYN Phase 3 trials, showing strong efficacy.

Menarini Regulatory Submissions Complete MAAs submitted to EMA/UK/Switzerland for obicetrapib; decisions anticipated in second half of 2026.

Operating Loss Decreased Annual loss for the year narrowed by $37.8M to $203.8M, despite revenue falling 50.6% to $22.5M.

Cash Position Supports Operations Ending cash, equivalents, and restricted cash totaled $491.3M as of December 31, 2025, sufficient for near-term needs.

Risk Factors

Clinical Stage and Profitability Risk Company remains clinical-stage, incurred $203.8M loss in 2025, and anticipates continued significant losses indefinitely.

Substantial Financing Required Requires substantial additional capital to achieve goals; failure to secure funding could delay or terminate product development efforts.

Increased Cash Used Investing Cash used in investing activities rose sharply to $174.9M in 2025, contributing to a $280.4M decrease in total cash balance.

Dependence on Obicetrapib Success Future success entirely dependent on successful clinical development, regulatory approval, and commercialization of obicetrapib.

Outlook

Complete PREVAIL Cardiovascular Outcomes Continue executing PREVAIL CVOT to evaluate MACE benefit; earliest conclusion expected end of 2026 or later.

Await European Regulatory Decisions Anticipate Menarini receiving regulatory decisions on MAAs from European regulators in the second half of 2026.

Initiate Alzheimer's Disease Trial Expect to initiate a new clinical trial evaluating obicetrapib in patients with early Alzheimer’s disease during 2026.

Pursue US Commercialization Strategy Current plan focuses on pursuing development and commercialization in the United States ourselves, considering additional partners.

Peer Comparison

Revenue (TTM)

ARWR

$1.09B

+4081.8%

LGND

$268.09M

+60.4%

SLNO

$190.41M

+0.0%

Gross Margin (Latest Quarter)

KYMR

2763.6%

-2680.7pp

LGND

143.6%

+2.6pp

CRNX

111.8%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ARWR	$9.12B	45.1	36.1%	19.5%
KYMR	$6.89B	-23.3	-29.1%	4.7%
PRAX	$6.87B	-24.1	-58.7%	0.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-77.9%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data